Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.35 |
| ▸ | PARP1 | P09874 | 3/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | PARP11 | Q9NR21 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29521546 | 0.80 | PARP10 (0.38) | S1PR1PARP10PARP1ADRB1PARP11 | |
| SCHEMBL19411016 | 0.80 | PARP10 (0.38) | S1PR1PARP10PARP1ADRB1PARP11 | |
| SCHEMBL26431777 | 0.76 | ALDH1A1 (0.34) | PARP10PARP1PARP11ALDH1A1MAPT | |
| SCHEMBL31161303 | 0.73 | NOTUM (0.42) | PARP10PARP1PARP11ALDH1A1MAPT | |
| SCHEMBL31161619 | 0.72 | ALDH1A1 (0.34) | PARP10PARP1PARP11ALDH1A1MAPT | |
| SCHEMBL28212644 | 0.72 | ALDH1A1 (0.34) | PARP10PARP11ALDH1A1MAPTNOTUM | |
| SCHEMBL17491542 | 0.71 | AR (0.40) | S1PR1ADRB1ALDH1A1MAPTAR | |
| SCHEMBL30550497 | 0.69 | ALDH1A1 (0.37) | PARP10ADRB1PARP11ALDH1A1MAPT | |
| SCHEMBL1735429 | 0.67 | PARP10 (0.60) | S1PR1PARP10PARP1PARP11AR | |
| SCHEMBL30038782 | 0.67 | PARP10 (0.60) | S1PR1PARP10PARP1PARP11AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2982670-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-11-07 | — | — | EP | disclosed |
| US-9624184-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-18 | — | — | US | disclosed |
| US-20160052897-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-25 | — | — | US | disclosed |
| EP-2982670-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052897-A1 | HETEROCYCLIC COMPOUND | PSEN1, PSEN2, BACE1 | S1PR1 2645/4885PARP10 3557/4885PARP1 2841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.